MASH

The AJMC® metabolic dysfunction-associated steatohepatitis compendium is a comprehensive resource for clinical news and expert insights for the condition, which was formerly known as nonalcoholic steatohepatitis.

Latest News
March 13th 2025

Lipid Metabolites Emerge as Noninvasive Diagnostic Tool in MASH

March 2nd 2025

Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases

February 27th 2025

Resmetirom Reduces Liver Stiffness in MASH-Compensated Cirrhosis

February 24th 2025

Efruxifermin Reverses MASH-Compensated Cirrhosis in Phase 2b SYMMETRY Study

February 19th 2025

Promising Potential for FGF21 Analogs in MASH Management

More News

MASH-related PLC is on the rise in young adult populations, causing concerns about how to best address the metabolic disease epidemic | image credit: https://gencraft.com/generate
February 6th 2025

MASH-Related PLC on the Rise in Young Adults

Kyle Munz
As a growing number of young adults with primary liver cancer (PLC) related to metabolic dysfunction–associated steatohepatitis (MASH) age, developing coherent strategies to combat the metabolic disease epidemic is critical.
The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics | image credit: TAW4 - stock.adobe.com
January 28th 2025

"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000

Kyle Munz
The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.
The management of MASH for those on a GLP-1RA could benefit from the edition of efruxifermin | image credit: Crystal Light - stock.adobe.com
January 27th 2025

Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes

Kyle Munz
Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.
MASH is the inflammatory, progressed form of MASLD | image credit: Rasi - stock.adobe.com
January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

Kyle Munz
Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).
Man holding liver illustration - SewcreamStudio - stock.adobe.com
June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

Rose McNulty
The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.
Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com
March 14th 2024

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

Laura Joszt, MA
The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
doctor checking liver
October 11th 2022

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

Laura Joszt, MA
There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.
fatty liver
November 23rd 2021

Improving Early Detection of Nonalcoholic Steatohepatitis on Ultrasound

Rose McNulty
A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo